Conolidine’s analgesic consequences stem from its conversation with non-opioid pain pathways. Unlike opioids, which bind to µ-opioid receptors inside the central anxious procedure, conolidine modulates alternate molecular targets. A Science Improvements review identified that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availabi... https://guyo061mio4.59bloggers.com/profile